NYSE:CUBI 21 December 2025

December 20, 2025 Briefing: Customers Bancorp (CUBI) Draws Fresh Institutional Interest as CUBI-F Preferred Redemption Hits; Rogers Sugar RSI.DB.F Signals Raise Data-Quality Questions; Japan Expands F-35A Basing at Chitose

Customers Bancorp completed redemption of its Series F preferred shares as institutional ownership reached 89.29% and analysts maintained a “Moderate Buy” consensus. In Canada, an AI-generated trading note circulated for Rogers Sugar’s RSI.DB.F debentures despite the TSX flagging the issue’s June maturity and delisting. Japan advanced plans to base F-35A jets at Chitose Air Base in Hokkaido, increasing airpower near Russia.

21 December 2025

NYSE:CUBI·Stock Market·TSX:RSI

Telix Pharmaceuticals Shares Surge 12.9% After TLX101-Px FDA NDA Resubmission and U.S. Manufacturing Expansion
March 20, 2026, 1:35 PM EDT. Telix Pharmaceuticals (ASX:TLX) jumped 12.9% following its March 2026 resubmission of the New Drug Application (NDA) for TLX101-Px (Pixclara) to the U.S. FDA. The investigational PET imaging agent targets brain cancer diagnosis, specifically glioma, with no current FDA-approved equivalents in the U.S. The resubmission includes new data after a prior Complete Response Letter and benefits from Orphan Drug and Fast Track designations. Concurrently, Telix's U.S. manufacturing build-out, including cyclotron orders for isotope production, aims to scale supply for future launches. While analysts project revenue of A$1.2 billion and earnings of A$111 million by 2029, the company faces risks from heavy R&D and manufacturing investments that may pressure margins if commercialization stalls. Investors are weighing potential near-term catalysts against execution and development uncertainties.